Dare Bioscience

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Daré Bioscience reports Q1 progress in women's health innovation

Daré Bioscience showcased progress in Q1 2024 with achievements in product commercialization and pipeline advancements, despite a reported comprehensive loss.
The company's focus on women's health innovation and commitment to driving value for stakeholders position them well for future growth.
While facing financial challenges and competitive pressures, Daré Bioscience has opportunities to capitalize on its strong pipeline and attract investor interest.
Continued momentum in Phase III studies and technology development present avenues for growth and market expansion in the women's health sector.

Dare Bioscience reports strong Q2 earnings, advances women's health therapies

Dare Bioscience delivered a robust Q2 2024 performance marked by cost efficiencies, revenue generation from strategic transactions, and progress in key product developments.
The company's focus on women's health and commitment to advancing therapies position it well for future growth and market leadership in a segment with significant unmet needs.
While facing challenges in market adoption and regulatory interactions, Dare Bioscience has opportunities to drive revenue growth, expand its market presence, and diversify its product portfolio.
Overall, Dare Bioscience's Q2 earnings call reflects a company on a positive trajectory, with a strong financial foundation and a strategic focus on advancing innovative solutions for women's health.

Daré Bioscience reports cost reductions and promising pipeline developments

Daré Bioscience showcased strong financial discipline with notable expense reductions and strategic funding acquisitions, positioning the company for sustainable growth.
Progress in late-stage candidates and FDA interactions signals promising developments in the pipeline, underscoring Daré's commitment to innovation in women's health.
While facing financial challenges and operational hurdles, Daré's focus on disruptive products and leveraging funding opportunities presents avenues for future success.
Overall, Daré Bioscience's Q3 performance reflects a balance of cost management, innovation, and strategic positioning in the healthcare market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organon & Co

Organon & Co (NYSE: OGN) will license global rights to Daré Bioscience Inc's (NASDAQ: DARE) Xaciato (clindamycin phosphate vaginal gel, 2%).  Xaciato is an FDA-approved medication for treating bacterial vaginosis (BV) in females 12 years of age and.

Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Clovis Oncology

First Wave BioPharma

Here's what you need to know about trading penny stocks on March 31st The post Trading Penny Stocks? Top Stock Market News for March 31st, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 31st, 2022

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™  (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective

Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 31, 2022, to review its financial results for the year ended December 31, 2021 and to provide a Company update.

Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held March 28-30, 2022.

Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences:

Daré Bioscience to Participate in Upcoming Conferences

Vinco Ventures

Maverix Metals Inc

Check these penny stocks out for your list on January 26th The post Trading Penny Stocks? Top Stock Market News for January 26th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for January 26th, 2022

ADMA Biologics

Oncolytics Biotech, Inc.

ReTo Eco-Solutions

Cheap penny stocks to watch right now. The post 4 Penny Stocks To Buy For Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Buy For Under $4 Right Now

Remark Hlds

Banco Santander

Which penny stocks are you buying right now? The post These Penny Stocks Climbed Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Penny Stocks Climbed Today, Here's Why

Dare (DARE) gets FDA approval for Xaciato (clindamycin phosphate) vaginal gel as a treatment for bacterial vaginosis.

Dare's (DARE) Xaciato Gets FDA Nod for Bacterial Vaginosis

The stock price of Daré Bioscience Inc (NASDAQ: DARE) increased by 10.52% in the most recent trading session. This is why it happened.

Dare Bioscience Stock (DARE): Why The Price Surged

The FDA has approved Daré Bioscience Inc (NASDAQ: DARE) Xaciato (DARE-BV1) to treat bacterial vaginosis.  Xaciato is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.

Daré Bioscience's One-Time Bacterial Vaginosis Treatment Scores FDA Approval

The stock price of Daré Bioscience Inc (NASDAQ: DARE) increased by over 3% pre-market today. This is why it happened.

Dare Bioscience Stock (DARE): Why The Price Increased Today

Atossa Genetics

Meten Holding Group Ltd.

Check these Reddit penny stocks out for your December 2021 watchlist The post 3 Reddit Penny Stocks For Your Early December Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Reddit Penny Stocks For Your Early December Watchlist

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q3 2021 Results - Earnings Call Transcript

Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3

Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update

An interactive conversation regarding the importance of industry and investor commitment to women's health innovation An interactive conversation regarding the importance of industry and investor commitment to women's health innovation

Daré Bioscience to Participate in Panel Discussion at DTC Perspectives' Xpectives.Health Summit, October 12-14, 2021

DARE-LARC1 Aims to Combine the Benefits of Long-acting Reversible Contraception with User-Controlled Flexibility to Pause or Resume Contraception as Desired DARE-LARC1 Aims to Combine the Benefits of Long-acting Reversible Contraception with User-Controlled Flexibility to Pause or Resume Contraception as Desired

Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1

Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.

Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy

SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the Cantor Fitzgerald Healthcare team September 27 – 30, 2021.

Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13 – 15, 2021.

Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

DarkPulse, Inc.

Evofem Biosciences Inc

AMC stock spikes again, leaving penny stocks rallying in its wake The post Best Penny Stocks To Buy Now? 3 To Watch As AMC Stock Sparks Rally appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 3 To Watch As AMC Stock Sparks Rally

Celsion

Meta Materials

Are these penny stocks on your watchlist in August 2021? The post Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Hot Penny Stocks to Watch Right Now, Have You Heard of These 3?

Cinedigm

Kosmos Energy

Reddit penny stocks are popular right now, here's 3 to watch The post 3 Penny Stocks on Reddit That Traders Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Dare Bioscience Stock (DARE)